Research graph
References from Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
Global ageing: successes, challenges and opportunities
10.12968/hmed.2019.0377 · 2020 · External reference
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
10.1016/s0140-6736(17)32448-0 · 2017 · External reference
Epidemiology of inflammatory bowel disease
10.1016/s0889-8553(01)00002-4 · 2002 · External reference
Epidemiology and risk factors for IBD
10.1038/nrgastro.2015.34 · 2015 · External reference
Past and future burden of inflammatory bowel diseases based on modeling of population-based data
10.1053/j.gastro.2019.01.002 · 2019 · External reference
European Crohn’s and Colitis organisation topical review on IBD in the elderly
10.1093/ecco-jcc/jjw188 · 2017 · External reference
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study
10.1136/gutjnl-2012-303864 · 2014 · External reference
Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study
10.1111/apt.17520 · 2023 · External reference
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. a Norwegian nationwide population-based registry study
10.1016/j.dld.2024.02.002 · 2024 · External reference
Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study
10.1097/mib.0000000000000993 · 2017 · External reference
Risk of age-related and disease-related complications and mortality in elderly-onset inflammatory bowel disease - a population-based study
10.1016/j.cgh.2025.01.020 · 2025 · External reference
Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease
10.1093/ecco-jcc/jjw054 · 2016 · External reference
Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies
10.1016/j.cgh.2020.02.048 · 2020 · External reference
Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden
10.1053/j.gastro.2017.10.034 · 2018 · External reference
Is it time to include older adults in inflammatory bowel disease trials? A call for action
10.1016/s2666-7568(22)00060-5 · 2022 · External reference
Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease
10.1097/mib.0000000000000747 · 2016 · External reference
Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry
10.1038/ajg.2012.218 · 2012 · External reference
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease
10.1016/j.cgh.2010.09.026 · 2011 · External reference
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease
10.1002/ibd.23026 · 2013 · External reference
Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients
10.1093/ecco-jcc/jjaa012 · 2020 · External reference
Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT
10.1111/apt.15214 · 2019 · External reference
High rates of mortality in geriatric patients admitted for inflammatory bowel disease management
10.1097/mcg.0000000000001458 · 2022 · External reference
IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
10.1136/gutjnl-2019-318835 · 2019 · External reference
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
10.1155/2005/269076 · 2005 · External reference
MatchIt: nonparametric preprocessing for parametric causal inference
10.18637/jss.v042.i08 · 2011 · External reference
Unresolved reference
2008 · External reference
Unresolved reference
2015 · External reference
Unresolved reference
2015 · External reference
Unresolved reference
2017 · External reference
Epidemiology of elderly onset IBD: a nationwide population-based cohort study
10.1016/j.cgh.2024.08.011 · 2025 · External reference
Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study
10.1136/bmjopen-2015-008597 · 2015 · External reference
Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases
10.1038/ajg.2014.313 · 2014 · External reference
Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? a 20-year national population-based cohort study
10.1097/mib.0000000000001031 · 2017 · External reference
Management of inflammatory bowel disease in the elderly: A review
10.1016/j.dld.2022.12.024 · 2023 · External reference
Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis
10.1016/j.cgh.2018.12.032 · 2019 · External reference
Comparative outcomes and safety of Vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases
10.1001/jamanetworkopen.2022.34200 · 2022 · External reference
Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults
10.1016/j.cgh.2021.08.047 · 2022 · External reference
Comparative safety and effectiveness of Ustekinumab and anti-TNF in elderly Crohn’s disease patients
10.1093/ibd/izae174 · 2025 · External reference
Ustekinumab and Vedolizumab are equally safe and effective in elderly Crohn’s disease patients
10.1007/s10620-022-07770-8 · 2023 · External reference
Risk of serious infections with Vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease
10.1016/j.cgh.2020.12.030 · 2022 · External reference
